Equities Analysts Offer Predictions for PLRX FY2029 Earnings

Pliant Therapeutics, Inc. (NASDAQ:PLRX) – Stock analysts at HC Wainwright upped their FY2029 EPS estimates for Pliant Therapeutics in a report released on Tuesday, March 4th. HC Wainwright analyst E. Arce now anticipates that the company will earn $1.80 per share for the year, up from their previous estimate of $1.75. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Pliant Therapeutics’ current full-year earnings is ($3.64) per share.

Pliant Therapeutics (NASDAQ:PLRX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.99) by $0.17.

A number of other analysts have also commented on PLRX. Oppenheimer reissued a “market perform” rating on shares of Pliant Therapeutics in a report on Monday, February 10th. Citigroup decreased their price target on Pliant Therapeutics from $4.00 to $1.50 and set a “neutral” rating for the company in a report on Tuesday. JPMorgan Chase & Co. cut Pliant Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, February 10th. Leerink Partners downgraded shares of Pliant Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $33.00 to $2.00 in a report on Monday. Finally, Canaccord Genuity Group reissued a “hold” rating and set a $4.00 price target (down from $43.00) on shares of Pliant Therapeutics in a research report on Monday, February 10th. Twelve research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $13.31.

Pliant Therapeutics Trading Up 12.6 %

NASDAQ:PLRX opened at $1.52 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 10.26 and a quick ratio of 10.26. Pliant Therapeutics has a one year low of $1.26 and a one year high of $16.52. The company has a market cap of $92.50 million, a PE ratio of -0.46 and a beta of 1.18. The firm has a 50-day moving average of $8.60 and a 200-day moving average of $11.66.

Insider Buying and Selling

In other Pliant Therapeutics news, insider Hans Hull sold 15,936 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $11.20, for a total value of $178,483.20. Following the completion of the sale, the insider now directly owns 211,558 shares of the company’s stock, valued at $2,369,449.60. The trade was a 7.01 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, General Counsel Mike Ouimette sold 10,230 shares of Pliant Therapeutics stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $10.99, for a total value of $112,427.70. Following the completion of the transaction, the general counsel now owns 70,544 shares in the company, valued at approximately $775,278.56. This represents a 12.66 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,855 shares of company stock worth $1,026,628 in the last quarter. 6.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Pliant Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of PLRX. China Universal Asset Management Co. Ltd. increased its stake in shares of Pliant Therapeutics by 10.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 12,903 shares of the company’s stock worth $170,000 after buying an additional 1,209 shares during the period. Swiss National Bank grew its holdings in Pliant Therapeutics by 1.6% in the 4th quarter. Swiss National Bank now owns 95,700 shares of the company’s stock worth $1,260,000 after acquiring an additional 1,500 shares during the last quarter. Atria Investments Inc grew its holdings in Pliant Therapeutics by 18.1% in the 4th quarter. Atria Investments Inc now owns 11,821 shares of the company’s stock worth $156,000 after acquiring an additional 1,812 shares during the last quarter. R Squared Ltd bought a new position in shares of Pliant Therapeutics during the fourth quarter valued at about $33,000. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Pliant Therapeutics by 0.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 459,384 shares of the company’s stock worth $6,050,000 after purchasing an additional 2,721 shares during the period. 97.30% of the stock is currently owned by institutional investors.

Pliant Therapeutics Company Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.